Jade Biosciences, Inc. (JBIO) - What Are Analysts Saying About This Stock?

Key Points

• Analyst sentiment is moderately bullish: Ten analysts give Jade Biosciences an average “Moderate Buy” rating, including six buys and two strong buys. The average 12-month price target is $51.75, although ratings range from sell to strong buy.
• JBIO remains a high-risk, development-stage biotech: The company reported a quarterly loss of $0.76 per share, missing the $0.66 consensus estimate, and analysts expect a full-year loss of $2.89 per share.
• The stock trades well below its recent high: JBIO opened at $13.83, compared with a 52-week range of $8.36 to $28.00, while its 50-day and 200-day moving averages stood at $17.95 and $19.74, respectively.

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) have been given an average recommendation of "Moderate Buy" by the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $51.75.

A number of equities research analysts have commented on JBIO shares. Weiss Ratings restated a "sell (d-)" rating on shares of Jade Biosciences in a report on Friday, September 11th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of Jade Biosciences in a research note on Thursday, October 1st. Jefferies Financial Group reiterated a "buy" rating and set a $48.00 price objective on shares of Jade Biosciences in a report on Tuesday, August 11th. BTIG Research upped their price objective on shares of Jade Biosciences from $74.00 to $77.00 and gave the company a "buy" rating in a report on Monday, August 10th. Finally, Wall Street Zen cut shares of Jade Biosciences from a "sell" rating to a "strong sell" rating in a research report on Saturday, September 12th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in JBIO. Quantinno Capital Management LP increased its holdings in shares of Jade Biosciences by 3.6% during the first quarter. Quantinno Capital Management LP now owns 30,551 shares of the company's stock valued at $429,000 after acquiring an additional 1,059 shares in the last quarter. Bank of America Corp DE raised its position in shares of Jade Biosciences by 2.9% during the first quarter. Bank of America Corp DE now owns 38,598 shares of the company's stock worth $542,000 after purchasing an additional 1,086 shares during the period. Squarepoint Ops LLC raised its position in shares of Jade Biosciences by 22.0% during the second quarter. Squarepoint Ops LLC now owns 54,456 shares of the company's stock worth $1,210,000 after purchasing an additional 9,806 shares during the period. Engineers Gate Manager LP bought a new position in shares of Jade Biosciences in the 2nd quarter worth $503,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Jade Biosciences in the 1st quarter worth $353,000.

Jade Biosciences Stock Up 2.7%

Shares of JBIO stock opened at $13.83 on Tuesday. The company has a market cap of $879.59 million, a price-to-earnings ratio of -7.20 and a beta of 1.64. Jade Biosciences has a 52 week low of $8.36 and a 52 week high of $28.00. The firm has a 50 day moving average of $17.95 and a 200-day moving average of $19.74.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Analysts anticipate that Jade Biosciences will post -2.89 earnings per share for the current year.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company's research and development efforts are directed toward antibody-based medicines designed to address significant unmet needs in immune-mediated conditions.

Jade's pipeline includes investigational therapeutic programs intended to modulate biological pathways involved in inflammation and immune-system activity. As a development-stage company, its products remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or reach the commercial market.

The company is headquartered in the United States and is developing its portfolio for potential use in global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.